Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors.

In addition, given that this is an observational retrospective study, there is risk for immortal time bias though our landmark analysis helped demonstrate similar patterns in median OS and showed a trend toward differences in TOT by race/ethnicity among patients who experienced irAEs.

also in 53,322 other papers